Loading...
XNAS
STTK
Market cap55mUSD
Jun 10, Last price  
1.16USD
1D
-2.52%
1Q
-5.69%
IPO
-93.89%
Name

Shattuck Labs Inc

Chart & Performance

D1W1MN
P/E
P/S
9.71
EPS
Div Yield, %
Shrs. gr., 5y
3.99%
Rev. gr., 5y
-10.36%
Revenues
6m
+245.26%
22,442,0009,887,0009,934,00030,017,000652,0001,657,0005,721,000
Net income
-75m
L-13.62%
-7,388,000-23,883,000-35,436,000-44,349,000-100,561,000-87,298,000-75,410,000
CFO
-61m
L-25.50%
-6,903,000-20,975,000-33,659,000-57,116,000-94,498,000-81,228,000-60,515,000
Earnings
Jul 30, 2025

Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
IPO date
Oct 09, 2020
Employees
105
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
5,721
245.26%
1,657
154.14%
652
-97.83%
Cost of revenue
86,288
97,656
107,356
Unusual Expense (Income)
NOPBT
(80,567)
(95,999)
(106,704)
NOPBT Margin
Operating Taxes
(1,384)
Tax Rate
NOPAT
(80,567)
(95,999)
(105,320)
Net income
(75,410)
-13.62%
(87,298)
-13.19%
(100,561)
126.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
(17)
48,170
171
BB yield
0.03%
-15.86%
-0.18%
Debt
Debt current
796
701
Long-term debt
5,012
6,812
8,404
Deferred revenue
Other long-term liabilities
Net debt
(67,975)
(123,017)
(152,175)
Cash flow
Cash from operating activities
(60,515)
(81,228)
(94,498)
CAPEX
(59)
(407)
(11,614)
Cash from investing activities
(8,511)
110,859
49,438
Cash from financing activities
787
48,616
171
FCF
(74,637)
(94,070)
(113,053)
Balance
Cash
72,987
130,625
161,280
Long term investments
Excess cash
72,701
130,542
161,247
Stockholders' equity
(381,713)
(306,301)
(219,884)
Invested Capital
463,845
455,208
400,944
ROIC
ROCE
EV
Common stock shares outstanding
50,758
42,600
42,379
Price
1.21
-83.03%
7.13
210.00%
2.30
-72.97%
Market cap
61,418
-79.78%
303,739
211.62%
97,471
-72.75%
EV
(6,557)
180,722
(54,704)
EBITDA
(76,738)
(91,957)
(103,631)
EV/EBITDA
0.09
0.53
Interest
3,073
Interest/NOPBT